Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 1/2 6Phase 1 5

Status

Completed 24Recruiting 18Terminated 14Unknown 7Withdrawn 6Not yet recruiting 2Active not recruiting 2

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 6

Sponsor

Cancer Type

Dermatologic 3Thoracic 1Other hematologic neoplasm 1Lymphoid 1Gynecologic 1Genitourinary 1CNS 1

Conditions

Melanoma 3Ovarian Cancer Metastatic 1Lymphoma, B-Cell 1Leukemia, B-Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1Adenocarcinoma of Lung 1

Interventions

Cyclophosphamide 28pembrolizumab 22Bevacizumab 18Fluorouracil 17Cisplatin 17Nivolumab 16Capecitabine 16Leucovorin 15Dexamethasone 14Carboplatin 13avelumab 12Oxaliplatin 12Radiosurgery 11Gemcitabine 11Rituximab 10Radiotherapy 10Lenalidomide 10ALT-803 10venetoclax 9fludarabine 9Taxes 9Omacor 9Azacitidine 9130-nm albumin-bound paclitaxel 9Paclitaxel 8Docetaxel 8Bortezomib 8fludarabine phosphate 7Melphalan 7Irinotecan 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 1/2 × Withdrawn × Interleukin-2 × Clear all
NCT05566223 2026-02-23

CheckCell-2

Intima Bioscience, Inc.

Phase 1/2 Withdrawn
Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung

NCT03098355 2024-03-18

Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies

Zhujiang Hospital

Phase 1/2 Withdrawn
LymphoidOther hematologic neoplasm

Leukemia, B-Cell, Lymphoma, B-Cell

NCT04389229 2020-12-16

OVSTAR

Immetacyte Ltd

Phase 1/2 Withdrawn
Gynecologic

Ovarian Cancer Metastatic

NCT03111901 2019-07-12

UVA-AM-002

University of Virginia

Phase 1/2 Withdrawn
DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma

NCT03297463 2018-08-01

Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma

Masonic Cancer Center, University of Minnesota

Phase 1/2 Withdrawn
CNSDermatologic

Brain Neoplasms, Melanoma

NCT01409187 2012-01-26

IPI-Biotherapy for Patients Previously Treated With Cytotoxic Drugs With Metastatic Melanoma

M.D. Anderson Cancer Center

Phase 1/2 Withdrawn
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡